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Background: The identification of microRNA-disease associations is critical for understanding the molecular
mechanisms of diseases. However, experimental determination of associations between microRNAs and diseases
remains challenging. Meanwhile, target diseases need to be revealed for some new microRNAs without any known
target disease association information as new microRNAs are discovered each year. Therefore, computational
methods for microRNA-disease association prediction have gained a lot of research interest.
Methods: Herein, based on the assumption that functionally related microRNAs tend to be associated with
phenotypically similar diseases, three inference methods were presented for microRNA-disease association
prediction, namely MBSI (microRNA-based similarity inference), PBSI (phenotype-based similarity inference) and
NetCBI (network-consistency-based inference). Global network similarity measure was used in the three methods to
predict new microRNA-disease associations.
Results: We tested the three methods on 242 known microRNA-disease associations by leave-one-out
cross-validation for prediction evaluation, and achieved AUC values of 74.83%, 54.02% and 80.66%, respectively.
The best-performed method NetCBI was then chosen for novel microRNA-disease association prediction. Some
associations strongly predicted by NetCBI were confirmed by the publicly accessible databases, which indicated the
usefulness of this method. The newly predicted associations were publicly released to facilitate future studies.
Moreover, NetCBI was especially applicable to predicting target diseases for microRNAs whose target association
information was not available.
Conclusions: The encouraging results suggest that our method NetCBI can not only provide help in identifying
novel microRNA-disease associations but also guide biological experiments for scientific research.
Keywords: MicroRNA-disease association prediction, Network similarity, Network consistencyBackground
Understanding the molecular mechanisms of diseases is
an important goal in biomedical research. In this post-
genomic era, numerous contributions [1-4], powered by
advanced high-throughput genomic technologies, have
been made towards this aim. Increasing evidence has re-
vealed that microRNAs (miRNAs) play important roles in
the development and progression of human diseases. An
example reported recently is miR-518a. This dysregulated
miRNA with some other miRNAs was discovered to be in-
volved in the development of cervical carcinoma through* Correspondence: zpzhang@mail.csu.edu.cn
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distribution, and reproduction in any mediumcontrolling apoptosis signalling pathways and cell cycle
regulation [5].
MiRNAs are a class of small non-coding RNAs typically
between 19 and 22 nucleotides in length, which mainly re-
press the expression of target mRNAs at the post-
transcriptional level by binding to the 3’-UTR of target
mRNAs through sequence-specific base pairing, resulting
in target mRNAs cleavage or translation inhibition [6-8].
In some cases miRNAs were also discovered to function
as positive regulators [9,10]. Many investigators have
reported that miRNAs are critical in tissue development
[11], cell growth [12], cellular signalling [13], and so on.
As such, the mutation of miRNAs, the dysfunction of
miRNA biogenesis and the dysregulation of miRNAs and
their targets may result to various diseases, such as lungntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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These studies have produced a large number of miRNA-
disease associations. Lu et al. [17] and Jiang et al. [18]
manually retrieved the associations between miRNAs and
diseases from literatures and constructed two curated da-
tabases, human miRNA-associated disease database
(HMDD) and miR2Disease, respectively. They aim to offer
comprehensive resources of experimentally confirmed
miRNA-disease associations. Yang et al. [19] also created a
publicly available database of Differentially Expressed
MiRNAs in human Cancers (dbDEMC) with the goal to
provide potential cancer-related miRNAs by in silico com-
puting. However, the current knowledge about miRNA-
disease associations is far from complete and experimental
identification of miRNA-disease associations by genomic
techniques is costly and time-consuming. Therefore there
is a strong incentive to develop computational methods
capable of detecting potential miRNA-disease associations
effectively, through which further biological experiments
can be guided.
Several computational approaches for miRNA-disease
association prediction have been proposed based on the
conclusions drawn by Lu et al. [17], who performed a com-
prehensive analysis to the human miRNA-disease associ-
ation data and disclosed that miRNAs tend to show
similar or different dysfunctional evidences for the similar
or different disease clusters, respectively. Under the as-
sumption that phenotypically similar diseases tend to be
associated with functionally related miRNAs, Zhang et al.
[20] used cardiovascular disease associated genes, miRNAs
clusters, family analysis and Gene Ontology to develop a
computational method to identify potential cardiovascular
disease related miRNAs. A limitation of this method is that
it has restricted application as the method ties to miRNAs
sets. Jiang et al. [21] proposed a computational model
based on the hypergeometric distribution to infer potential
miRNA-disease associations by prioritizing the entire hu-
man microRNAome for diseases of interest. The notion
that functionally related miRNAs tend to be associated
with phenotypically similar diseases was reconfirmed in
their manuscript. Although miRNA functional network,
disease similarity network and known miRNA-disease as-
sociations were integrated in their work, only the neigh-
bour information of each miRNA was used in their scoring
system. Prediction accuracy would be increased by taking
advantage of the global network similarity information.
Another limitation is that in silico predicted associations
were used as data sources in this method. It is known that
these predicted associations used as data sources have
some false-positive and false-negative results, thus influen-
cing the final prediction accuracy. Chen et al. [22] adopted
global network similarity measures and developed Random
Walk with Restart for MiRNA-Disease Association
(RWRMDA) to infer potential miRNA-disease associationsby implementing random walk on the miRNA-miRNA
functional similarity network. It was indicated in their
work that global network similarity measures are better
suited to capture the associations between diseases and
miRNAs than traditional local network similarity mea-
sures. Good prediction performance was demonstrated in
their experimental results. However, phenotype similarity
information is not used in this method and RWRMDA
does not work for diseases which do not have any known
associated miRNAs. According to the assumption that
miRNAs implicated in a specific tumor phenotype will
show aberrant regulation of their target genes, Xu et al.
[23] introduced an approach based on the miRNA target-
dysregulated network (MTDN), constructed by combining
computational target prediction with miRNA and mRNA
expression profiles in tumor and nontumor tissues, to
prioritize novel disease miRNAs. The drawback of this
method is that negative samples are used, while there are
no verified negative miRNA-disease associations in reality.
Computational prediction methods are important ways
to choose the most promising miRNA-disease associations
for further experimental examinations. The main difficulty
of this task lies in the rarity of known miRNA-disease asso-
ciations. In this paper, three inference methods, MBSI
(microRNA-based similarity inference), PBSI (pheno-
type-based similarity inference) and NetCBI (network-
consistency-based inference), were introduced to predict
potential miRNA-disease associations based on the global
network similarity measure and the assumption that func-
tionally related miRNAs tend to be associated with pheno-
typically similar diseases. MiRNA functional similarity
network, disease similarity network and known miRNA-
disease associations were integrated in our work. For
the three methods, each miRNA-disease association was
scored and high prediction scores could be expected to
have high probabilities of miRNA-disease associations.
Benchmark dataset with known miRNA-disease associa-
tions was used to assess the performance of our proposed
methods. The best-performed method NetCBI was then
selected for potential miRNA-disease association predic-
tion. Some predicted associations with high-ranks were
manually checked and were confirmed from the publicly
available databases. We take these as strong evidence to
support the practical application of our approach. Our
comprehensively predicted miRNA-disease associations
also enable us to suggest many potential miRNA-disease
associations, which can offer help in further experiments
and hence increase research productivity.
Results
MiRNA-disease association network construction
and analysis
In this study, we first focus on the verified miRNA–disease
associations. The set of 242 known miRNA–disease
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ard’ data, and is used for evaluating the performance of
our proposed methods in the cross-validation experi-
ments as well as training data in the comprehensive
prediction. We constructed the miRNA–disease associ-
ation network using a bipartite graph representation
(see Figure 1) and analysed some statistics for the
miRNA-disease association network. In the bipartite
graph, the heterogeneous nodes correspond to either
miRNAs or diseases, and edges correspond to associations
between them. An edge is placed between a miRNA node
and a disease node if the disease is known to associate with
the miRNA.
Figure 2 shows the degree distributions for miRNAs
and diseases in the miRNA–disease association network.
The degree of the miRNA (respective disease) node is
the number of diseases that the miRNA has associa-
tions with (respectively the number of miRNAs targeting
the disease).
Table 1 details some statistics for the miRNA-disease as-
sociation network, such as average degree of miRNAs andFigure 1 MiRNA-disease phenotype network (MP network). The MP ne
between miRNAs and diseases. The network is prepared by Pajek (http://vlaaverage degree of diseases. Inspection of the miRNA–
disease association network shows that the miRNAs and
their target diseases tend to be densely clustered, while it
also comprises a few small unconnected components.
Performance evaluation of the proposed methods
The three methods, MBSI, PBSI and NetCBI, were tested
on the 242 known miRNA-disease associations to assess
their power to infer potential miRNA-disease associations.
We performed a leave-one-out cross-validation on each
method. For PBSI, the miRNA associations of each query
disease were left out once as the testing case. For MBSI
and NetCBI, the associations between a query miRNA and
all its disease phenotypes including the target disease
phenotype(s) were removed in the leave-one-out cross-
validation. We prioritized the entire associations according
to the scores derived from the three scoring systems.
We calculated the sensitivity and specificity for each
threshold. Sensitivity refers to the percentage of the asso-
ciations whose ranking is higher than a given thre-
shold, namely the ratio of the successfully predictedtwork is generated by using 242 experimentally verified associations
do.fmf.uni-lj.si/pub/networks/pajek/).
Figure 2 Degree distributions for miRNAs and diseases in the miRNA-disease phenotype network. The top panel shows the histograms of
the degree distributions of miRNAs. The bottom panel shows the histograms of the degree distributions of diseases.
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total experimentally verified miRNA-disease associations.
Specificity refers to the percentage of associations that are
below the threshold. A receiver-operating characteristics
(ROC) curve was plotted by varying the threshold, and the
value of area under curve (AUC) was calculated. Take
NetCBI as an example. The values of all disease associa-
tions of one miRNA are available after one round of leave-
one-out cross validation. Each value is taken as a threshold
for calculating true positive fraction (TPF) and false posi-
tive fraction (FPF).Then ROC curve is plotted and AUC
value is calculated according to these TPFs and FPFs. We fi-
nally report the average AUC values of the three methods.
Figure 3 shows the ROC curves and average AUC values of
our three inference methods for miRNA-disease association
prediction. For NetCBI, the result produced by the best
parameters in the leave-one-out cross-validation wasTable 1 Statistics for the miRNA-disease association network
No. of miRNAs No. of diseases No. of miRNA-disease associatio
99 51 242reported. When our methods were tested on the 242 ex-
perimentally verified miRNA-disease associations, three
AUC values of 74.83%, 54.02% and 80.66% were achieved,
suggesting that the two methods, MBSI and NetCBI, can
recover the known experimentally-verified miRNA-disease
associations, and therefore have the potential to infer new
miRNA-disease associations.
Effects of parameters in NetCBI
There are two parameters in our method NetCBI. To in-
vestigate the selection of the two parameters for the per-
formance of NetCBI, we set various values for them and
calculated the AUC values in the framework of leave-one
-out cross-validation. Additional file 1 details the effects
of the two parameters on the cross validation results in
the benchmark dataset. After a comprehensive searching,
the parameters (α=0.1, β=0.1) led to best AUC result arens Average degree of miRNAs Average degree of diseases
2.44 4.75
Figure 3 ROC curves and AUC values of the three proposed
methods to predict miRNA-disease associations in the
benchmark dataset by leave-one-out cross-validation tests.
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ation prediction.
To get an unbiased estimate, we conducted a nested
leave-one-out cross validation in NetCBI. We split the 99
miRNA samples into three parts-97 miRNAs for training,
1 miRNA for test and 1 miRNA for validation. Parameter
optimization is conducted within the 98 miRNAs (97
miRNAs for training and 1 miRNA for test) and perform-
ance evaluation is based on the validation part. Leave-
one-out cross validation was conducted in each inner loop
for parameter optimization, which included 98 iterations.
The outer loop of performance evaluation was also based
on leave-one-out cross validation, which included 99 itera-
tions. We finally received a slightly reduced AUC value of
79.77%, with parameters α=0.2618 ± 0.01, β=0.2618 ± 0.01.
It can be observed that the results received in NetCBI are
quite robust to parameter changes.
Comparison with other methods
Until recently, several computational methods have been
proposed for miRNA-disease association prediction. Dif-
ferent models have been constructed based on different
data features, such as Gene Ontology, miRNA function
similarity value, miRNAs clusters, and so on, which makes
performance comparison difficult. An AUC value of
75.80% was achieved under the assumption of the hy-
pergeometric distribution for prioritizing miRNAs in [21].
When this model was applied to diseases without any
known related miRNAs, a reduced AUC value of 69.51%
was obtained. Unlike the method presented in [21], our
proposed methods make full use of global network simi-
larity measures, including miRNA-miRNA functional
similarity and disease phenotype similarity, and the best-
performed approach NetCBI received a higher AUC value
of 80.66%. Although another higher AUC value of 86.17%was achieved in [22], phenotype similarity information
was not used in this method and it was not applicable to
diseases without any known related miRNAs.
Comprehensive prediction for unknown miRNA-
disease associations
After confirming the usefulness of our methods, we chose
the best-performed method NetCBI to conduct a compre-
hensive prediction of unknown associations between all
possible miRNAs and diseases. In the inference process
for these predictions, we trained NetCBI with all the
known associations. Parameters α and β are set to be 0.1.
We ranked the non-associating pairs with respect to their
association scores. The prediction results for unknown
miRNA-disease associations with the top 100 highest
scores are shown in Figure 4. The full list of the top 100
prediction results can be obtained from the Additional
file 2. Furthermore, we manually checked the top 10 pre-
dicted associations from the latest online versions of
HMDD [17], miR2Disease [18] and dbDEMC [19] data-
bases. We confirmed that 6 associations (Table 2) are now
annotated in at least one of the three databases. Meanwhile
a p-value of 0.006 is received using Fisher's exact test. We
take these as strong evidence to support the practical appli-
cation of our approach. Note that the predicted associa-
tions that are not reported yet may also exist in reality.
Discussion
The current difficulties of developing computational me-
thods for the prediction of miRNA-disease associations lie
in three aspects. Firstly, the known miRNA-disease associ-
ations are rare. Secondly, negative samples are hard or
even impossible to select as there are no verified negative
miRNA-disease associations. Thirdly, association predic-
tion should also be made to miRNAs without any known
target disease association information as new miRNAs are
discovered each year.
Here, we presented three computational methods for
the prediction of miRNA-disease associations. All the
three methods do not use negative samples. The essential
difference of the three methods is the definition of similar-
ity. MBSI is based on miRNA functional similarity, and
PBSI is based on phenotype similarity, whereas NetCBI is
based on both of the two similarity values. Based on the
foundations of previous research [24,25], the best-
performed method NetCBI focuses on improving detec-
tion of miRNA-disease associations by integrating the
miRNA functional similarity information and the human
disease similarity information to better summarize sparse
associations for a global comparison of all possible
miRNA-disease associations. The global relevance be-
tween a query miRNA and all the miRNAs is measured
with graph Laplacian scores in NetCBI. The global rele-
vance between a target disease and all disease phenotypes
Figure 4 Newly predicted miRNA-disease association network with the top 100 highest scores. The network is prepared by Pajek
(http://vlado.fmf.uni-lj.si/pub/networks/pajek/).
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miRNA network and the disease network simultaneously
to analyze associations between miRNAs and diseases.
Comparison among the three proposed methods indi-
cated that integration of miRNA function similarity valueTable 2 The newly confirmed miRNA-disease associations
in the top 10 predicted results by NetCBI
miRNA OMIM Disease ID Rank Source
hsa-let-7a 133239 1 HMDD
hsa-let-7a 605027 2 HMDD
hsa-let-7a 603956 3 dbDEMC
hsa-let-7a 150699 4
hsa-let-7a 131440 5 HMDD
hsa-let-7a 161550 6 HMDD
hsa-let-7a 226150 7
hsa-let-7a 266600 8 HMDD
hsa-miR-16 161550 9
hsa-miR-21 150699 10and disease phenotype similarity value can improve pre-
diction performance. The worst AUC value of PBSI on the
benchmark dataset indicated that prediction based on
phenotype similarity alone was poor. Compared with
some existing methods that also utilized the miRNA func-
tional similarity information and the human disease simi-
larity information, NetCBI is more flexible in handling the
association prediction because NetCBI is able to predict
disease phenotypes for new miRNAs whose target disease
association information is not available. This feature is
very useful because new miRNAs are discovered each year
and their target diseases need to be revealed.
One previous research related with this study is the
prioritization of disease miRNAs based on the hyper-
geometric distribution [21], but only the neighbour infor-
mation of each miRNA was used, which limited its
prediction accuracy. The most recent study related with
our work is miRNA-disease association inference based on
random walk on a miRNA-miRNA functional similarity
network [22]. However, phenotype similarity information
was not taken into consideration, and newly detectable
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ated miRNAs.
Despite the encouraging results of NetCBI, there are
also limitations. NetCBI depends heavily on network simi-
larity measure, and the known experimentally verified
miRNA-disease associations were rare. Therefore, inte-
grating other bioinformatics sources, such as Gene Ontol-
ogy, might improve model performance. From a technical
viewpoint, the performance of our method could be im-
proved by using more accurate similarity information
designed for miRNAs and diseases.
Conclusions
We presented three similarity-based methods to predict
associations between miRNAs and human diseases. We
took advantage of both OMIM phenotype similarity in-
formation and miRNA functional similarity information
in the best-performed method NetCBI. Best performance
among the three methods and further confirmation of
some strongly-predicted miRNA-disease associations in
publicly accessible databases indicate the realistic appli-
cation of NetCBI. The top 100 potential miRNA-disease
associations predicted by NetCBI are released publicly to
facilitate biological experiments for the contribution to
the identification of true miRNA-disease associations.
The methods we proposed will be an important bioinfor-
matics resource in biomedical research to identify the
roles of miRNAs in human diseases.
Methods
Data sources
The benchmark dataset (see Additional file 3) used in
this manuscript is downloaded from [21,26,27]. Here
below we provide a brief description.
The miRNA-miRNA functional similarity data
The miRNA-miRNA functional similarity scores were
downloaded from http://cmbi.bjmu.edu.cn/misim/ [26]. In
this dataset, a functional similarity score for each miRNA
pair is calculated based on the observation that genes with
similar functions are often associated with similar diseases.
The miRNA functional similarity scores have been suc-
cessfully used to infer novel human miRNA-disease asso-
ciations in [22].
The disease phenotype similarity data
We downloaded the disease phenotype similarity scores
from the MimMiner [27], developed by van Driel et al.
who computed a phenotype similarity score for each
phenotype pair by the text mining analysis of their pheno-
type descriptions in the Online Mendelian Inheritance in
Man (OMIM) database [28]. The phenotypic similarity
scores have been successfully used to predict or prioritize
disease related protein-coding genes [29,30].The human miRNA-disease association data
We downloaded the 270 known experimentally verified
miRNA-disease associations provided in [21]. We dis-
covered that 19 miRNAs could not be searched in [26].
After removing the 19 miRNAs from the 270 known
associations, we finally received 242 verified miRNA-
disease associations consisting of 99 miRNAs and 51 dis-
ease phenotypes.
Method description
We denote the miRNA set as M = {m1,m2, . . .,mn} and
the phenotype set as P = {p1, p2, . . ., pm}, the miRNA-
disease associations can be described as a bipartite MP
graph G(M, P, E), where E = {eij :mi ∈M, pj ∈ P}. A link is
drawn between mi and pj when the miRNA mi is associ-
ated with the phenotype pj. The MP bipartite network
can be presented by an n×m adjacent matrix {aij}, where
aij=1 if mi and pj is linked, while all other unknown
miRNA-disease pairs are labeled as 0 to indicate they
are going to be predicted. We define M(n*n), P(m*m),
and a(n*m) as the adjacency matrix of the miRNA func-
tional similarity network, the disease phenotype si-
milarity network, and the miRNA-disease association
network, respectively.
MicroRNA-based similarity inference (MBSI)
The basic idea of this method is: if a miRNA is associ-
ated with a disease, then other miRNAs similar to the
miRNA will be recommended to be associated with the
disease. For an MP pair mi-pj, a linkage between mi and






where S(mi,ml) is miRNA functional similarity value be-
tween miRNAs mi and ml.
Phenotype-based similarity inference (PBSI)
The basic idea of this method is: if a miRNA is associated
with a disease, then the miRNA will be recommended to
be associated with other similar diseases. For an MP pair









Where S(pj, pl) is disease phenotype similarity value
between diseases pj and pl.
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The basic idea of network consistency is that, if miRNAs
are ranked by their relevance to a query miRNA, and
phenotypes are ranked by their relevance to the hidden
target phenotype of the query miRNA, the top-ranked
miRNAs and the top-ranked disease phenotypes should
be highly connected by known associations. Unlike the
above two inference methods, NetCBI integrates the
miRNA-miRNA functional similarity network data and
the disease phenotype similarity network data. The idea
of network consistency has been successfully used to
predict gene-phenotype associations in [24]. The solid
foundation for the algorithm can be traced back to [25].
We formulate a graph query problem for miRNA and
disease association discovery. The query miRNA is rep-
resented by a binary vector m = [m1,m2, . . .,mn]
T denot-
ing the miRNA membership against the miRNA set, i.e.
each mi=1 if miRNA i is the query miRNA, otherwise
mi=0. Similarly, the list of target phenotypes is given by
another binary vector p = [p1, p2, . . ., pm]
T and phenotype
j is a target phenotype if pj=1.
To make full use of global network similarity informa-
tion, we compute the global relevance score between the
query miRNA m and all the miRNAs based on the graph
Laplacian of the miRNA functional similarity network M
(n*n). We first normalize M as M ¼ M :; ið Þ=sum M :; ið Þð Þ,
where i is the column number of M. A vector em of graph












In Equation (3), the first term is a smoothness penalty,
which forces connected miRNAs to receive similar
scores, and the second term ensures the consistency
with the query miRNA. Parameter α ∈ (0, 1) balances the
contributions from the two penalties. The close solution
to Equation (3) is
em ¼ 1 αð Þ I  α―M 1m ð4Þ
Similarly, graph Laplacian scores can be derived to
measure the relevance between the phenotypes and the
target phenotype p with the close solution
ep ¼ 1 βð Þ I  βP 1p ð5Þ
where P is the normalized P and parameter β ∈ (0, 1).
Our method uses consistency in networks to measure
whether the query miRNA m and a target phenotype
p show coherent association with the known miRNA-
phenotype associations. Specifically, given the graph
Laplacian scores em , which ranks the miRNAs by their
relevance to the query miRNA m, and the graph Laplacianscores ep, which ranks the phenotypes by their relevance to
the hidden target phenotype p, NetCBI measures whether
the associations given by a are connecting miRNAs and
phenotypes with similar scores in em and ep. We simply go
through each phenotype and compute a Pearson cor-
relation coefficient score against the query miRNA m for
each case.
NetCBIcorr em;ep; að Þ ¼ corr aep; emð Þ ð6Þ
Finally, the phenotype(s) with the highest score(s) is
chosen as the target phenotype(s).
Additional files
Additional file 1: The effects of two parameters in NetCBI.
Additional file 2: 100 top-ranked potential miRNA-disease
associations. Each line represents a potential association between miRNAs
and human diseases, including miRNA ID, OMIM ID and OMIM name.
Additional file 3: The benchmark dataset used in this manuscript.
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